LAG3 and colorectal carcinoma: In a Phase 1 study investigating tebotelimab, an IgG4 antibody that binds and inhibits LAG-3 and PD-1 concomitantly or independently, PR was achieved in 6.8% of patients with advanced solid tumours, with best response of SD for the 2 evaluable patients with CRC [29].